MiR-135b Plays a Neuroprotective Role by Targeting GSK3β in MPP+-Intoxicated SH-SY5Y Cells

Disease Markers

Volumn 2017, Issue , 2017, Pages

  Zhang, Jianlei ^a   Liu, Wei ^a   Wang, Yabo ^a   Zhao, Shengnan ^a   Chang, Na ^a  

^a HENAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CASPASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 1BETA; MICRORNA; MICRORNA 135B; NITROPRUSSIDE SODIUM; RHO ASSOCIATED KINASE 2; RHO KINASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; MIRN135 MICRORNA, MOUSE;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUCIFERASE ASSAY; NEUROPROTECTION; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUNEL ASSAY; UPREGULATION; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; GENETICS; METABOLISM; MOUSE; NERVE CELL; TUMOR CELL LINE;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; GLYCOGEN SYNTHASE KINASE 3 BETA; MICE; MICRORNAS; NEURONS;

EID: 85018986195     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2017/5806146     Document Type: Article

References (40)

1. T. Gasser, "Molecular pathogenesis of Parkinson disease: insights from genetic studies," Expert Reviews in Molecular Medicine, vol. 11, Article ID e22, 2009.
2. E. R. Dorsey, R. Constantinescu, J. P. Thompson et al., "Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030," Neurology, vol. 68, no. 5, pp. 384-386, 2007.
3. A. J. Lees, J. Hardy, and T. Revesz, "Parkinson's disease," The Lancet, vol. 373, no. 9680, pp. 2055-2066, 2009.
4. M. J. Devine, K. Gwinn, A. Singleton, and J. Hardy, "Parkinson's disease and alpha-synuclein expression," Movement Disorders, vol. 26, no. 12, pp. 2160-2168, 2011.
5. S. Theodore, S. Cao, P. J. McLean, and D. G. Standaert, "Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease," Journal of Neuropathology & Experimental Neurology, vol. 67, no. 12, pp. 1149-1158, 2008.
6. S. H. Appel, "Inflammation in Parkinson's disease: cause or consequence?" Movement Disorders, vol. 27, no. 9, pp. 1075-1077, 2012.
7. E. C. Hirsch and S. Hunot, "Neuroinflammation in Parkinson's disease: a target for neuroprotection?" The Lancet Neurology, vol. 8, no. 4, pp. 382-397, 2009.
8. A. D. Thome and A. S. Harms, "microRNA-155 regulates alpha-synuclein-induced inflammatory responses in models of Parkinson disease," The Journal of Neuroscience, vol. 36, no. 8, pp. 2383-2390, 2016.
9. E. Doxakis, "Principles of miRNA-target regulation in metazoan models," International Journal of Molecular Sciences, vol. 14, no. 8, pp. 16280-16302, 2013.
10. P. S. Choi, L. Zakhary, W. Y. Choi et al., "Members of the miRNA-200 family regulate olfactory neurogenesis," Neuron, vol. 57, no. 1, pp. 41-55, 2008.
11. D. De Pietri Tonelli, J. N. Pulvers, C. Haffner, E. P. Murchison, G. J. Hannon, and W. B. Huttner, "miRNAs are essential for survival and differentiation of newborn neurons but not for expansion of neural progenitors during early neurogenesis in the mouse embryonic neocortex," Development, vol. 135, no. 23, pp. 3911-3921, 2008.
12. L. Qiu, W. Zhang, E. K. Tan, and L. Zeng, "Deciphering the function and regulation of microRNAs in Alzheimer's disease and Parkinson's disease," ACS Chemical Neuroscience, vol. 5, no. 10, pp. 884-894, 2014.
13. L. Alvarez-Erviti, Y. Seow, A. H. Schapira, M. C. Rodriguez-Oroz, J. A. Obeso, and J. M. Cooper, "Influence of microRNA deregulation on chaperone-mediated autophagy and alphasynuclein pathology in Parkinson's disease," Cell Death & Disease, vol. 4, no. 3, Article ID e545, 2013.
14. Y. Liu, S. Liao, H. Quan, Y. Lin, J. Li, and Q. Yang, "Involvement of microRNA-135a-5p in the protective effects of hydrogen sulfide against Parkinson's disease," Cellular Physiology and Biochemistry, vol. 40, no. 1-2, pp. 18-26, 2016.
15. C. M. Chong, M. Shen, Z. Y. Zhou et al., "Discovery of a benzofuran derivative (MBPTA) as a novel ROCK inhibitor that protects against MPP(+)-induced oxidative stress and cell death in SH-SY5Y cells," Free Radical Biology & Medicine, vol. 74, pp. 283-293, 2014.
16. S. Guha, J. P. Cullen, D. Morrow et al., "Glycogen synthase kinase 3 beta positively regulates Notch signaling in vascular smooth muscle cells: role in cell proliferation and survival," Basic Research in Cardiology, vol. 106, no. 5, pp. 773-785, 2011.
17. S. Shin, L. Wolgamott, Y. Yu, J. Blenis, and S. O. Yoon, "Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation," Proceedings of the National Academy of Sciences, vol. 108, no. 47, pp. E1204-E1213, 2011.
18. P. Watcharasit, G. N. Bijur, L. Song, J. Zhu, X. Chen, and R. S. Jope, "Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53," The Journal of Biological Chemistry, vol. 278, no. 49, pp. 48872-48879, 2003.
19. N. Embi, D. B. Rylatt, and P. Cohen, "Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase," European Journal of Biochemistry, vol. 107, no. 2, pp. 519-527, 1980.
20. P. Lei, S. Ayton, A. I. Bush, and P. A. Adlard, "GSK-3 in neurodegenerative diseases," International Journal of Alzheimer's Disease, vol. 2011, no. 2, p. 189246, 2011.
21. L. Yu, J. Huang, D. Zhai et al., "MAPT rs242562 and GSK3B rs334558 are associated with Parkinson's disease in central China," BMC Neuroscience, vol. 15, no. 1, p. 54, 2014.
22. C. A. Rankin, Q. Sun, and T. C. Gamblin, "Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology," Molecular Neurodegeneration, vol. 2, no. 1, p. 12, 2007.
23. S. Majd, J. H. Power, and H. J. Grantham, "Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways," BMC Neuroscience, vol. 16, no. 1, p. 69, 2015.
24. M. Golpich, E. Amini, F. Hemmati et al., "Glycogen synthase kinase-3 beta (GSK-3beta) signaling: implications for Parkinson's disease," Pharmacological Research, vol. 97, pp. 16-26, 2015.
25. W. Wang, Y. Yang, C. Ying et al., "Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity," Neuropharmacology, vol. 52, no. 8, pp. 1678-1684, 2007.
26. X. Yang, X. Wang, F. Nie et al., "miR-135 family members mediate podocyte injury through the activation of Wnt/beta-catenin signaling," International Journal of Molecular Medicine, vol. 36, no. 3, pp. 669-677, 2015.
27. M. Gerlach, P. Riederer, H. Przuntek, and M. B. Youdim, "MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease," European Journal of Pharmacology, vol. 208, no. 4, pp. 273-286, 1991.
28. M. Molasy, A. Walczak, J. Szaflik, J. P. Szaflik, and I. Majsterek, "MicroRNAs in glaucoma and neurodegenerative diseases," Journal of Human Genetics, vol. 62, no. 1, pp. 105-112, 2016.
29. C. P. Yang, Z. H. Zhang, L. H. Zhang, and H. C. Rui, "Neuroprotective role of microRNA-22 in a 6-hydroxydopamine-induced cell model of Parkinson's disease via regulation of its target gene TRPM7," Journal of Molecular Neuroscience, vol. 60, no. 4, pp. 445-452, 2016.
30. Y. Zhou, M. Lu, R. H. Du et al., "MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuro-inflammation in the pathogenesis of Parkinson's disease," Molecular Neurodegeneration, vol. 11, no. 1, p. 1, 2016.
31. Y. Zhang, H. Xing, S. Guo, Z. Zheng, H. Wang, and D. Xu, "MicroRNA-135b has a neuroprotective role via targeting of beta-site APP-cleaving enzyme 1," Experimental and Therapeutic Medicine, vol. 12, no. 2, pp. 809-814, 2016.
32. Y. C. Chung, H. W. Ko, E. Bok et al., "The role of neuroinflammation on the pathogenesis of Parkinson's disease," BMB Reports, vol. 43, no. 4, pp. 225-232, 2010.
33. C. Barcia, C. M. Ros, V. Annese et al., "IFN-gamma signaling, with the synergistic contribution of TNF-alpha, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease," Cell Death & Disease, vol. 2, no. 4, p. e142, 2011.
34. J. Waak, S. S. Weber, A. Waldenmaier et al., "Regulation of astrocyte inflammatory responses by the Parkinson's diseaseassociated gene DJ-1," The FASEB Journal, vol. 23, no. 8, pp. 2478-2489, 2009.
35. L. Qian, H. M. Wu, S. H. Chen et al., "Beta2-adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway," The Journal of Immunology, vol. 186, no. 7, pp. 4443-4454, 2011.
36. E. Beurel, S. M. Michalek, and R. S. Jope, "Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3)," Trends in Immunology, vol. 31, no. 1, pp. 24-31, 2010.
37. H. M. Wang, T. Zhang, Q. Li, J. K. Huang, R. F. Chen, and X. J. Sun, "Inhibition of glycogen synthase kinase-3beta by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes," Neurochemistry International, vol. 63, no. 5, pp. 345-353, 2013.
38. C. J. Yuskaitis and R. S. Jope, "Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammationinduced neurotoxicity," Cellular Signalling, vol. 21, no. 2, pp. 264-273, 2009.
39. D. Hernandez-Baltazar, M. E. Mendoza-Garrido, and D. Martinez-Fong, "Activation of GSK-3beta and caspase-3 occurs in nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine," PloS One, vol. 8, no. 8, Article ID e70951, 2013.
40. V. Lulli, M. Buccarelli, M. Martini et al., "miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal," Oncotarget, vol. 6, no. 35, pp. 37241-37256, 2015.